Full interview: Arcturus Therapeutics working to 'transform the pharmaceutical industry' with its therapeutics
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) CEO Joseph Payne tells Proactive that the company which specializes in developing messenger RNA medicine for rare diseases, is working towards 'transforming the pharmaceutical industry' with its therapeutics.
Payne says San Diego-based Arcturus has four therapeutics in pre-clinical studies, including its lead therapeutics LUNAR-CF and LUNAR-OTC. He is pleased with how its 2Q financial highlights are propelling these programs into the clinic.
Quick facts: Arcturus Therapeutics
Market Cap: $175.57 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE